clinical trial · NCT07015697
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Daiichi Sankyo·phase1·recruiting·n = 76
Recurrent or Metastatic Solid TumorsTrastuzumab Deruxtecan
brief summary
This is a dose escalation, and dose expansion study of T-DXd plus hyaluronidase administered subcutaneously, to assess the safety, tolerability, PK and efficacy of SC T-DXd plus hyaluronidase in participants with metastatic solid tumors.
started
Jul 17, 2025
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Mar 20, 2026
official title
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol